COVID-19 vaccine antibodies remain highly active against the newly emerged California and New York variants of SARS-CoV-2, according to the latest research from a collaborative team from The University of Texas Medical Branch at Galveston and Pfizer/BioNTech. The results provide new laboratory evidence to support mass immunization with the current, highly safe, and effective vaccines to end the COVID-19 pandemic. As the COVID-19 pandemic persists, SARS-CoV-2 continues to evolve in patients through accumulated mutations. Each mutation brings with it...